Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,612 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 3,662 · Balance 75,612 F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson 2021 Irrevocable Trust | 129,877 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 129,877 F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson 2015 Irrevocable Trust | 74,581 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,581 F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Cynthia E. Anderson 2015 Irrevocable Trust | 74,581 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 74,581 F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Kenneth C. Anderson Revocable Trust | 3,623 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,623 F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Cynthia E. Anderson Revocable Trust | 3,623 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,623 F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2026.
F3: Shares held by the Kenneth C. Anderson 2021 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F4: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F5: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F6: Shares held by the Kenneth C. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F7: Shares held by the Cynthia E. Anderson Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GiftCommon Stock | 2,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 47,316 F2 · shares: On April 13, 2021, Cynthia E. Anderson received a distribution of 2,278 shares of the Issuer's common stock from the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 20:39 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GiftCommon Stock | 2,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026665 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,435 F1 · shares: On April 13, 2021, Kenneth C. Anderson received a distribution of 2,278 shares of the Issuer's common stock from the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 233 | $37.51 | $8,739.83 |
DisclosureSEC source: 0001209191-21-025665 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,157 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 889 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 11 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,446 Underlying: Common Stock · 889 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments, with the first installment vesting on October 1, 2020. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 121 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 10 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: The Form 3 filed on October 1, 2020 included an incorrect number of underlying securities in Table II, Column 3 (118). F7 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on January 1, 2017, with the remainder vesting in 16 equal quarterly installments thereafter. F6 · derivative.underlying_shares: The Form 3 filed on October 1, 2020 included an incorrect number of underlying securities in Table II, Column 3 (118). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 538 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 Underlying: Common Stock · 538 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 889 | $4.98 | $4,427.22 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 3 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 121 | $2.11 | $255.31 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:34 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 538 | $2.11 | $1,135.18 |
DisclosureSEC source: 0001209191-21-005374 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries B Preferred Stock · Derivative | 142,857 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 12 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cynthia E. Anderson 2015 Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 16,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F5 · ownership.nature: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries B Preferred Stock · Derivative | 142,857 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 11 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kenneth C. Anderson 2015 Irrevocable Trust Disclosed balance after: 0 Underlying: Common Stock · 16,939 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F4 · ownership.nature: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 347,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 10 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cynthia E. Anderson 2016 Grantor Retained Annuity Trust Disclosed balance after: 0 Underlying: Common Stock · 41,244 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F3 · ownership.nature: Shares held the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 347,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kenneth C. Anderson 2016 Grantor Retained Annuity Trust Disclosed balance after: 0 Underlying: Common Stock · 41,244 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 152,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 18,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 152,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · derivative · entry 7 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 16,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 6 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cynthia E. Anderson 2015 Irrevocable Trust Disclosed balance after: 16,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F5 · ownership.nature: Shares held by the Cynthia E. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 16,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 5 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kenneth C. Anderson 2015 Irrevocable Trust Disclosed balance after: 16,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F4 · ownership.nature: Shares held by the Kenneth C. Anderson 2015 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 41,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 4 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Cynthia E. Anderson 2016 Grantor Retained Annuity Trust Disclosed balance after: 63,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F3 · ownership.nature: Shares held the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 41,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 3 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kenneth C. Anderson 2016 Grantor Retained Annuity Trust Disclosed balance after: 63,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 18,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 45,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 01:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 18,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027696 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 01, 2020 Filed Oct 6, 2020 01:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027443 · doc4.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2030-09-30 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.